Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Invyncible vs Obu Health

Invyncible
Graded #303

Higher grade

vs+1.1000000000000014
Obu Health
Graded #332

Lower grade

The verdict

Invyncible takes it — 61/100 to 59.9/100, but only just.

Invyncible grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Invyncible is a Florida-based telehealth platform offering semaglutide and tirzepatide programs for weight management. Obu Health is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueInvyncible +11
55
44
Dose & formulationEven
64
64
Clinical oversightObu Health +14
70
84
Labs & monitoringObu Health +1
52
53
FulfillmentObu Health +9
65
74
Contract termsInvyncible +30
61
31
Invyncible · left barObu Health · right bar

The numbers

MetricInvyncibleObu Health
WeighScore61/10059.9/100
GradeCC
Scorecard rank#303#332
Semaglutide$192/mo (0.5 mg dose, compounded)$190/mo (starting dose, plus a separate fee, compounded)
Tirzepatide$210/mo (compounded)$239/mo (starting dose, plus a separate fee, compounded)
Coverage40 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Invyncible

Graded #303 · C

Strengths

  • Corporate parent disclosed (Nationwide Telemedicine, LLC) — better than most competitors hiding behind trade names
  • Physical corporate address published (St. Petersburg, FL)
  • LegitScript verification seal displayed
  • No long-term commitment required
  • Offers both semaglutide and tirzepatide programs

Where it loses points

  • Pricing not disclosed on the public site — fully gated behind signup
  • Drug forms (compounded vs brand, injection vs oral) not disclosed
  • 503A vs 503B designation not specified
  • Pharmacy partner not named
  • States served not listed publicly
Obu Health

Graded #332 · C

Strengths

  • LegitScript-certified with publicly displayed ID (44206977)
  • Two named 503A compounding-pharmacy partners (Manifest Pharmacy SC + RX Compounding Store FL) — transparency above category baseline
  • Lower advertised semaglutide starting price ($190) than most multi-product peer platforms
  • Multi-product offering (GLP-1s + NAD+ + sermorelin + generic ED + birth control) for single-platform users
  • 24-hour US board-certified physician response window

Where it loses points

  • Per-dose pricing tiers not transparently published on product pages — only 'starting from' prices visible
  • No explicit state-coverage list disclosed; FAQ confirms restrictions exist 'based on state' without enumeration
  • Medical director not named publicly
  • No published consultation fee disclosure — unclear whether physician visit is included in medication price
  • All sales final per FAQ ('Federal and State law do not allow medication returns')

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard